|Expense Ratio (net)||0.78%|
|Morningstar Risk Rating||★★★|
|Last Cap Gain||0.00|
|Inception Date||Nov 3, 2003|
|Average for Category||N/A|
Below we share with you three top-ranked, large-cap value mutual funds. Each has earned a Zacks Mutual Fund Rank #1 (Strong Buy)
Morningstar readers share their top reasons for cutting an investment loose.
Pfizer's stock may currently be out of favor, but the drug giant's fortunes will soon turn due to its strong cash flow and undervalued pipeline.